// App-Quantinova.ai

BSH19‐PO‐095 : Indirect Treatment Comparison of Venetoclax plus Rituximab with B‐cell Receptor Inhibitors in Patients with Relapsed/Refractory Chronic Lymphocytic Leukaemia

Researchers

Presenter

  • A. Mato

Principal Investigators

  • G. Follows

  • K. Sail

  • I. Diakite

  • D. Nicoloso

  • B. Dietz

  • J. Maher

  • D. Alexiou

  • V. Chirikov

Medical Centers

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • Department of Oncology, Cambridge University NHS Foundation Trust (Addenbrookes Hospital), Cambridge, United Kingdom

  • AbbVie, Inc., North Chicago, IL

  • Pharmerit International, Bethesda, Maryland, United States

  • AbbVie Deutschland GmbH & Co, KG, GPRD, Ludwigshafen, Germany

  • AbbVie Inc., North Chicago, Illinois, United States

Locations

  • United States

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Bendamustine

  • Idelalisib

  • Venetoclax

  • Ibrutinib

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02005471

  • NCT01611090

  • NCT01569295

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved